{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T07:04:07Z","timestamp":1776582247148,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Pamela and Nick Gelsomini Breast Surgical Oncology Fellowship Fund"},{"name":"Rob and Karen Hale Distinguished Chair in Surgical Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1245\/s10434-023-13898-2","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T13:01:53Z","timestamp":1689166913000},"page":"5978-5987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intraoperative Pathology Assessment May Lead to Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer Patients Undergoing Upfront Mastectomy"],"prefix":"10.1245","volume":"30","author":[{"given":"Robert M.","family":"Pride","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charity C.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faina","family":"Nakhlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Laws","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna C.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"12","key":"13898_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol"},{"issue":"3","key":"13898_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"AE Giuliano","year":"2016","unstructured":"Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the american college of surgeons oncology group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016;264(3):413\u201320. https:\/\/doi.org\/10.1097\/SLA.0000000000001863.","journal-title":"Ann Surg"},{"issue":"10","key":"13898_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al.,International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30380-2.","journal-title":"Lancet Oncol"},{"issue":"4","key":"13898_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"\u00c1 S\u00e1volt","year":"2017","unstructured":"S\u00e1volt \u00c1, P\u00e9ley G, Polg\u00e1r C, Udvarhelyi N, Rubovszky G, Kov\u00e1cs E, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla - surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2016.12.011.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"13898_CR5","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1245\/s10434-012-2386-3","volume":"19","author":"S Milgrom","year":"2012","unstructured":"Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, et al. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol. 2012;19(12):3762\u201370. https:\/\/doi.org\/10.1245\/s10434-012-2386-3.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"13898_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1245\/s10434-016-5605-5","volume":"24","author":"E FitzSullivan","year":"2017","unstructured":"FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, et al. Outcomes of sentinel lymph node-positive breast cancer patients treated with mastectomy without axillary therapy. Ann Surg Oncol. 2017;24(3):652\u20139. https:\/\/doi.org\/10.1245\/s10434-016-5605-5.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"13898_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1245\/s10434-016-5608-2","volume":"24","author":"HS Cody 3rd","year":"2017","unstructured":"Cody HS 3rd. Extending ACOSOG Z0011 to encompass mastectomy: what happens without RT? Ann Surg Oncol. 2017;24(3):621\u20133. https:\/\/doi.org\/10.1245\/s10434-016-5608-2.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"13898_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10549-022-06727-9","volume":"196","author":"W Gao","year":"2022","unstructured":"Gao W, Lu S, Zeng Y, Chen X, Shen K. Axilla lymph node dissection can be safely omitted in patients with 1\u20132 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis. Breast Cancer Res Treat. 2022;196(1):129\u201341. https:\/\/doi.org\/10.1007\/s10549-022-06727-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"13898_CR9","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1245\/s10434-021-10726-3","volume":"29","author":"O Kantor","year":"2022","unstructured":"Kantor O, Means J, Grossmith S, Dey T, Bellon JR, Mittendorf EA, et al. Optimizing axillary management in clinical T1\u20132N0 mastectomy patients with positive sentinel lymph nodes. Ann Surg Oncol. 2022;29(2):972\u201380. https:\/\/doi.org\/10.1245\/s10434-021-10726-3.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"13898_CR10","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1245\/s10434-019-07901-y","volume":"26","author":"BM Raber","year":"2019","unstructured":"Raber BM, Lin H, Shen Y, Shaitelman SF, Bedrosian I. Trends in regional nodal management of breast cancer patients with low nodal burden. Ann Surg Oncol. 2019;26(13):4346\u201354. https:\/\/doi.org\/10.1245\/s10434-019-07901-y.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"13898_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-018-5009-2","volume":"173","author":"A Hennigs","year":"2019","unstructured":"Hennigs A, K\u00f6pke M, Fei\u00dft M, Riedel F, Rezai M, Nitz U, et al. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? Breast Cancer Res Treat. 2019;173(2):429\u201338. https:\/\/doi.org\/10.1007\/s10549-018-5009-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"13898_CR12","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1245\/s10434-022-11759-y","volume":"29","author":"AP Stafford","year":"2022","unstructured":"Stafford AP, Hoskin TL, Day CN, Sanders SB, Boughey JC. Contemporary axillary management in cT1-2N0 breast cancer with one or two positive sentinel lymph nodes: factors associated with completion axillary lymph node dissection within the national cancer database. Ann Surg Oncol. 2022;29(8):4740\u20139. https:\/\/doi.org\/10.1245\/s10434-022-11759-y.","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"13898_CR13","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1200\/JCO.19.02896","volume":"38","author":"SA McLaughlin","year":"2020","unstructured":"McLaughlin SA, Brunelle CL, Taghian A. Breast cancer-related lymphedema: risk factors, screening, management, and the impact of locoregional treatment. J Clin Oncol. 2020;38(20):2341\u201350. https:\/\/doi.org\/10.1200\/JCO.19.02896.","journal-title":"J Clin Oncol"},{"key":"13898_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.radonc.2018.07.006","volume":"131","author":"ML Gregorowitsch","year":"2019","unstructured":"Gregorowitsch ML, Verkooijen HM, Houweling A, Fuhler N, Koelemij R, Schoenmaeckers EJP, et al., UMBRELLA Study Group. Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients. Radiother Oncol. 2019;131:221\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2018.07.006.","journal-title":"Radiother Oncol"},{"issue":"3","key":"13898_CR15","doi-asserted-by":"publisher","first-page":"S234","DOI":"10.1097\/SAP.0000000000001864","volume":"82","author":"AR Johnson","year":"2019","unstructured":"Johnson AR, Kimball S, Epstein S, Recht A, Lin SJ, Lee BT, et al. Lymphedema incidence after axillary lymph node dissection: quantifying the impact of radiation and the lymphatic microsurgical preventive healing approach. Ann Plast Surg. 2019;82(3):S234\u201341. https:\/\/doi.org\/10.1097\/SAP.0000000000001864.","journal-title":"Ann Plast Surg"},{"issue":"13","key":"13898_CR16","doi-asserted-by":"publisher","first-page":"8037","DOI":"10.1245\/s10434-022-12238-0","volume":"29","author":"AD Williams","year":"2022","unstructured":"Williams AD, Khan AJ, Sevilimedu V, Barrio AV, Morrow M, Mamtani A. Omission of intraoperative frozen section may reduce axillary overtreatment among clinically node-negative patients having upfront mastectomy. Ann Surg Oncol. 2022;29(13):8037\u201343. https:\/\/doi.org\/10.1245\/s10434-022-12238-0.","journal-title":"Ann Surg Oncol"},{"issue":"25","key":"13898_CR17","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2008.21.7018","volume":"27","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the national cancer data base. J Clin Oncol. 2009;27(25):4177\u201381. https:\/\/doi.org\/10.1200\/JCO.2008.21.7018.","journal-title":"J Clin Oncol"},{"key":"13898_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01565","author":"SAL Bartels","year":"2022","unstructured":"Bartels SAL, Donker M, Poncet C, Sauv\u00e9 N, Straver ME, van de Velde CJH, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981\u201322023 AMAROS trial. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.22.01565.","journal-title":"J Clin Oncol"},{"issue":"9","key":"13898_CR19","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","volume":"29","author":"C Tinterri","year":"2022","unstructured":"Tinterri C, Gentile D, Gatzemeier W, Sagona A, Barbieri E, Testori A, et al., SINODAR-ONE Collaborative Group. Preservation of axillary lymph nodes compared with complete dissection in T1\u20132 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE Multicenter randomized clinical trial. Ann Surg Oncol. 2022;29(9):5732\u201344. https:\/\/doi.org\/10.1245\/s10434-022-11866-w.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"13898_CR20","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1245\/s10434-017-5982-4","volume":"24","author":"SA McLaughlin","year":"2017","unstructured":"McLaughlin SA, Staley AC, Vicini F, Thiruchelvam P, Hutchison NA, Mendez J, Feldman SM, et al. Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema: recommendations from a multidisciplinary expert ASBrS panel: part 1: definitions, assessments, education, and future directions. Ann Surg Oncol. 2017;24(10):2818\u201326. https:\/\/doi.org\/10.1245\/s10434-017-5982-4.","journal-title":"Ann Surg Oncol"},{"key":"13898_CR21","unstructured":"National Comprehensive Cancer Network Guideline. Breast cancer. Version 4 2023. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 9 Apr 2023"},{"issue":"10","key":"13898_CR22","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1245\/s10434-021-10441-z","volume":"28","author":"CS Cortina","year":"2021","unstructured":"Cortina CS, Bergom C, Craft MA, Fields B, Brazauskas R, Currey A, et al. A national survey of breast surgeons and radiation oncologists on contemporary axillary management in mastectomy patients. Ann Surg Oncol. 2021;28(10):5568\u201379. https:\/\/doi.org\/10.1245\/s10434-021-10441-z.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"13898_CR23","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1245\/s10434-018-6519-1","volume":"25","author":"M Moossdorff","year":"2018","unstructured":"Moossdorff M, Nakhlis F, Hu J, Barry WT, Losk K, Haskett C, et al. The potential impact of AMAROS on the management of the axilla in patients with clinical T1\u20132N0 Breast cancer undergoing primary total mastectomy. Ann Surg Oncol. 2018;25(9):2612\u20139. https:\/\/doi.org\/10.1245\/s10434-018-6519-1.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"13898_CR24","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1245\/s10434-018-6525-3","volume":"25","author":"S Grossmith","year":"2018","unstructured":"Grossmith S, Nguyen A, Hu J, Plichta JK, Nakhlis F, Cutone L, et al. Multidisciplinary management of the axilla in patients with cT1-T2 N0 breast cancer undergoing primary mastectomy: results from a prospective single-institution series. Ann Surg Oncol. 2018;25(12):3527\u201334. https:\/\/doi.org\/10.1245\/s10434-018-6525-3.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"13898_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.clbc.2021.02.013","volume":"21","author":"J Davis Jr","year":"2021","unstructured":"Davis J Jr, Boughey JC, Hoskin TL, Day CN, Cheville JC, Piltin MA, et al. Locoregional management of the axilla in mastectomy patients with one or two positive sentinel nodes: the role of intraoperative pathology. Clin Breast Cancer. 2021;21(5):458\u201365. https:\/\/doi.org\/10.1016\/j.clbc.2021.02.013.","journal-title":"Clin Breast Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13898-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T14:03:02Z","timestamp":1694440982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13898-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["13898"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13898-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"21 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Elizabeth A. Mittendorf reports compensated service on scientific advisory boards for Astra Zeneca, BioNTech and Merck; uncompensated service on steering committees for Bristol Myers Squibb and Roche\/Genentech; and institutional research support from Roche\/Genentech (via SU2C grant) and Gilead. She also reports research funding from Susan Komen for the Cure, for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. Tari A. King reports speaker honoraria and an advisory board role for Exact Sciences, and is on the global advisory board of Besins Healthcare. Robert M. Pride, Charity C. Glass, Faina Nakhlis, Alison Laws, Anna C. Weiss, Jennifer R. Bellon, and Olga Kantor report no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}